These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17409936)

  • 41. GSTP1
    Walia HK; Singh N; Sharma S
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S739-S752. PubMed ID: 34780261
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients.
    Jun L; Haiping Z; Beibei Y
    Swiss Med Wkly; 2009 Dec; 139(49-50):724-8. PubMed ID: 20047135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparison of treatment efficacy of the second and the third generations of chemoradiotherapy regimens containing platinum on advanced non-small cell lung cancer].
    Wang YM; Guo LJ; Li LS; Li P; Zheng J; Li L
    Ai Zheng; 2005 Dec; 24(12):1514-7. PubMed ID: 16351804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
    Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
    Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
    [TBL] [Abstract][Full Text] [Related]  

  • 45. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881.
    Wagner H; Lad T; Piantadosi S; Ruckdeschel JC
    Chest; 1994 Dec; 106(6 Suppl):348S-354S. PubMed ID: 7988262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients.
    Zhou F; Yu Z; Jiang T; Lv H; Yao R; Liang J
    Swiss Med Wkly; 2011; 141():w13275. PubMed ID: 22009704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer.
    Soh LT; Tan EH; Ang PT
    Singapore Med J; 1998 Aug; 39(8):357-8. PubMed ID: 9844496
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.
    Deng X; Yang X; Cheng Y; Liu X; Li X; Zhao R; Qin C; Lu Q; Yin C
    Sci Rep; 2015 Sep; 5():14000. PubMed ID: 26354850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
    Han B; Gao G; Wu W; Gao Z; Zhao X; Li L; Qiao R; Chen H; Wei Q; Wu J; Lu D
    Lung Cancer; 2011 May; 72(2):238-43. PubMed ID: 20943283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Kim HT; Lee JE; Shin ES; Yoo YK; Cho JH; Yun MH; Kim YH; Kim SK; Kim HJ; Jang TW; Kwak SM; Kim CS; Ryu JS
    J Clin Oncol; 2008 Dec; 26(36):5972-9. PubMed ID: 19018088
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Li YQ; Zhang XY; Chen J; Yin JY; Li XP
    J Cancer Res Ther; 2018; 14(4):881-886. PubMed ID: 29970670
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of glutathione S-transferase (GST) genetic polymorphisms with treatment outcome of cisplatin-based chemotherapy for advanced non-small cell lung cancer in a Chinese population.
    Xiao HL; Yang ZT; Han F; Wei HX
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The association between the GSTP1 A313G and GSTM1 null/present polymorphisms and the treatment response of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients: a meta-analysis.
    Yang Y; Xian L
    Tumour Biol; 2014 Jul; 35(7):6791-9. PubMed ID: 24729086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis.
    Shen X; Wang J; Yan X; Ren X; Wang F; Chen X; Xu Y
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1285-302. PubMed ID: 27154175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of glutathione S transferases P1 (Ile105Val) variants on the risk of GSTp, phosphorylated c-Jun kinase, and P53 phenotypic expression and their implications on overall survival outcomes in non-small cell lung cancer patients treated with chemotherapy.
    Pathak AK; Husain N; Shukla S; Pandey RK; Kant S; Bala L
    Mutat Res; 2022; 824():111775. PubMed ID: 35124341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Glutathione S-transferase pi polymorphism contributes to the treatment outcomes of advanced non-small cell lung cancer patients in a Chinese population.
    Chen JB; Wang F; Wu JJ; Cai M
    Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525853
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.
    De Troia B; Dalu D; Filipazzi V; Isabella L; Tosca N; Ferrario S; Gambaro AR; Somma L; Fasola C; Cheli S; Clementi E; De Francesco D; Falvella FS; Cattaneo MT
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):803-808. PubMed ID: 30796464
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North China.
    Ge J; Tian AX; Wang QS; Kong PZ; Yu Y; Li XQ; Cao XC; Feng YM
    PLoS One; 2013; 8(6):e67589. PubMed ID: 23826324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.